Published in J Clin Oncol on August 31, 2009
The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol (2012) 1.63
A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Hum Mol Genet (2011) 1.24
Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother (2014) 1.17
Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. Nat Rev Drug Discov (2015) 1.14
Interleukin-12 as an adjuvant for induction of protective antibody responses. Cytokine (2010) 0.94
Genes involved in systemic and arterial bed dependent atherosclerosis--Tampere Vascular study. PLoS One (2012) 0.90
Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol (2015) 0.89
Global promoter methylation analysis reveals novel candidate tumor suppressor genes in natural killer cell lymphoma. Clin Cancer Res (2015) 0.82
Biomarkers and the genetics of early neoplastic lesions. Cancer Biomark (2010) 0.78
Molecular genetic study of novel biomarkers for early diagnosis of oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal (2015) 0.77
Inhibition of human diffuse large B-cell lymphoma growth by JC polyomavirus-like particles delivering a suicide gene. J Transl Med (2015) 0.75
Retracted The IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignancies. J Clin Invest (2004) 1.68
Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia (2004) 1.56
Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. Blood (2005) 1.37
Mechanisms of immune evasion of human neuroblastoma. Cancer Lett (2005) 1.17
Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin Cancer Res (2010) 1.09
CXCL12 does not attract CXCR4+ human metastatic neuroblastoma cells: clinical implications. Clin Cancer Res (2006) 1.07
Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg-/- mice. Clin Cancer Res (2012) 1.05
Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc Natl Acad Sci U S A (2007) 1.03
Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells. Cell Res (2011) 1.02
Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression. PLoS One (2012) 1.01
Immunogenicity of human neuroblastoma. Ann N Y Acad Sci (2004) 1.00
Chemokines in neuroectodermal tumour progression and metastasis. Semin Cancer Biol (2008) 0.93
Heterogeneous expression of interleukin-18 and its receptor in B-cell lymphoproliferative disorders deriving from naive, germinal center, and memory B lymphocytes. Clin Cancer Res (2004) 0.93
Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells. Blood (2010) 0.92
CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow. Cancer Immunol Immunother (2007) 0.91
Direct inhibition of human acute myeloid leukemia cell growth by IL-12. Immunol Lett (2010) 0.90
IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions. PLoS One (2009) 0.89
Interleukin-30 expression in prostate cancer and its draining lymph nodes correlates with advanced grade and stage. Clin Cancer Res (2013) 0.88
Targeting acute myeloid leukemia cells with cytokines. J Leukoc Biol (2012) 0.83
New perspectives for melanoma immunotherapy: role of IL-12. Curr Mol Med (2009) 0.82
Interleukin-27 and interleukin-23 modulate human plasmacell functions. J Leukoc Biol (2011) 0.81
Methylation of the IL-12Rbeta2 gene as novel tumor escape mechanism for pediatric B-acute lymphoblastic leukemia cells. Cancer Res (2006) 0.81
Anti-leukemic properties of IL-12, IL-23 and IL-27: differences and similarities in the control of pediatric B acute lymphoblastic leukemia. Crit Rev Oncol Hematol (2011) 0.81
Human TCRγδ+ T cells represent a novel target for IL-27 activity. Eur J Immunol (2012) 0.80
The IL-18 antagonist IL-18-binding protein is produced in the human ovarian cancer microenvironment. Clin Cancer Res (2013) 0.80
Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target. Blood (2008) 0.79
IL-27 in human secondary lymphoid organs attracts myeloid dendritic cells and impairs HLA class I-restricted antigen presentation. J Immunol (2014) 0.79
Cytokines and microRNA in pediatric B-acute lymphoblastic leukemia. Cytokine Growth Factor Rev (2011) 0.77
IL-21: a new player in the control of isotype switch in Peyer's patches. J Leukoc Biol (2009) 0.76
Graft-versus-host disease is ameliorated by blocking of IL-21 signaling. Immunotherapy (2012) 0.75
IL-22 as key factor of thymic regeneration. Immunotherapy (2012) 0.75
Tumor-associated macrophages: from cancer supporters to tumoricidal effectors. Immunotherapy (2012) 0.75
The enigmatic role of interleukin-12 in the pathogenesis of Sjögren's syndrome: comment on the article by Vosters et al. Arthritis Rheum (2010) 0.75
Novel insights into the role of interleukin-27 and interleukin-23 in human malignant and normal plasma cells. Clin Cancer Res (2011) 0.75